Serbia Pharmaceuticals & Healthcare Q1 2019
The Serbian pharmaceutical market is among the least developed in the Central and Eastern European region. Lower-value medicines will continue to dominate the market given the low purchasing power of patients and the country’s weakintellectual property laws, weakening opportunities for innovative drugmakers. However, growth will remain positive in the comingyears, supported by an ageing population as well as government efforts to expand and modernise public healthcare.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook